NTRA vs SYRE
Natera, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
70
Buy
| Metric | NTRA | SYRE |
|---|
| AI Score |
67
|
70
|
| Price |
$309.83
|
$103.56
|
| P/E Ratio |
-228.51×
|
-52.23×
|
| ROE |
-12.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
65.3%
|
0.0%
|
| Debt / Equity |
0.13×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.7
|
49.5
|
| Beta |
1.514
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for NTRA versus SYRE.
SYRE leads by 3 points.
SYRE scores 70/100 (Buy) versus NTRA at 67/100 (Buy).
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 33.7% signals elevated volatility — Risk
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical